Yuan Ou
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
From clinical evidence to biological mechanisms: GPRC5B as a key mediator of metabolic syndrome-associated prostate cancer.
Journal: International journal of biological macromolecules
Published: January 07, 2026
Effects of Digital Interventions on Symptom Improvement and Quality of Life in Patients With Overactive Bladder: Systematic Review and Meta-Analysis.
Journal: Journal of medical Internet research
Published: December 05, 2025
ANXA2-mediated Phagocytosis Generates AR+ Macrophages to Confer Enzalutamide Resistance in Prostate Cancer.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: December 02, 2025
Mapping the immune landscape of PCa: From tumor microenvironment to therapeutics.
Journal: Biochimica et biophysica acta. Reviews on cancer
Published: October 27, 2025
Cancer Cell-Intrinsic Cholesterol Induces Lipid-Associated Macrophage Differentiation via SP1 Palmitoylation to Promote Prostate Cancer Progression.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 15, 2025
Epidemiology of Early Onset Prostate Cancer: Global Patterns, Risk Factors, and Projections Through 2040.
Journal: Annals of surgical oncology
Published: May 12, 2025
The role of phosphatidylinositol (18:1_18:1) in benign prostatic hyperplasia: an integrated study of Mendelian randomization and network pharmacology.
Journal: World journal of urology
Published: April 06, 2025
Inflammation-Targeted and Antioxidative Poly(Ferulic Acid) Nanoparticles Directly Treat Chronic Nonbacterial Prostatitis via Inhibiting Pyroptosis by Disrupting Nrf2/KEAP1 Multimer Formation and as a Robust Drug Carrier.
Journal: Advanced healthcare materials
Published: March 30, 2025
Rising Prevalence of Urinary Incontinence and Nocturia Amid the COVID-19 Pandemic.
Journal: Neurourology and urodynamics
Published: February 19, 2025
An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer.
Journal: Journal of translational medicine
Published: October 12, 2024
Showing 1-10 of 10
Last Updated: 09/26/2026